JOHN LYDON to Ribonucleoside Diphosphate Reductase
This is a "connection" page, showing publications JOHN LYDON has written about Ribonucleoside Diphosphate Reductase.
Connection Strength
0.115
-
Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance. Neoplasia. 2014 May; 16(5):390-402.
Score: 0.115